Business Context and Reporting Period
This Form 6-K filing by Redhill Biopharma Ltd. covers the month of November 2021, with the report dated November 17, 2021. The company is a foreign private issuer based in Tel Aviv, Israel, and files annual reports on Form 20-F.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes rather than financial performance.
Material Changes
The primary material change disclosed is the voluntary resignation of Mr. Alessandro Della Chà from the Company's Board of Directors, effective November 16, 2021, for personal reasons.
Management Commentary and Risks
Dror Ben-Asher, Chairman and CEO, issued a statement thanking Mr. Della Chà for his service and contribution to Redhill Biopharma and wishing him well in the future. The filing does not contain specific guidance, outlook, or discussion of financial risks or contingencies.
Key Facts for Investor Verification
- Mr. Alessandro Della Chà resigned from the Board of Directors effective November 16, 2021.
- The resignation was voluntary and cited personal reasons.
- No financial data or operational metrics are included in this specific filing.
- The filing is incorporated by reference into multiple Registration Statements on Forms S-8 and F-3.